LAB
Standard BioTools Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.69
+1.72%Aug 25, 2026, 17:55 UTC
Standard BioTools Inc. reported Q2 2026 financial results with revenue declining 7.6% year over year to $20.1 million and net loss widening to $26.8 million.
Source:Jul 28, 2026, 12:00 UTC
Standard BioTools sold its mass cytometry business to Multiplex Bio, and Illumina bought out contingent payments to advance Standard BioTools' merger with Treeline Biosciences.
Source:Jul 28, 2026, 00:00 UTC
Standard Biotools received approximately $30 million cash from Illumina in exchange for waiving its rights to the 2026 Illumina Earnout and agreeing to terminate the existing Royalty and License Agreements between the parties.
Jul 20, 2026, 11:30 UTC
Standard BioTools filed a registration statement for its transaction with Treeline Biosciences.
Source:Jun 8, 2026, 11:30 UTC
Standard BioTools and Treeline Biosciences announced a merger agreement, with the combined company to operate as Treeline Biosciences.